SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending as part of a broader surge in quantum computing stocks, with community members actively discussing its potential for significant gains. Optimism stems from upcoming events, potential government contracts, and the company's technology for optimization, though some express concerns about the current valuation. Overall, there's a sense of FOMO (fear of missing out) driving interest in QBTS.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following news of a memorandum of understanding with the U.S. Department of Energy, sparking excitement about quantum technologies in space. Community discussions revolve around the company's growth potential, comparisons to other tech stocks, and debate over valuation amid a short squeeze. Some are closely watching for a potential Trump-related announcement that could further boost the stock.

BGM Group Ltd. is a pharmaceutical and chemical company. It focuses on the research, development, manufacture, marketing, and sale of oxytetracycline products, licorice products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Licorice products include Gan Di Xin, Qilian Shan Licorice Extract, and Qilian Shan Licorice Liquid Extract. The Oxytetracycline products consists of Qilian Shan Oxytetracycline Tablets and Qilian Shan Oxytetracycline Active Pharmaceutical Ingredients (API). The TCMD product includes Ahan antibacterial paste, which is made from a mixture of traditional Chinese herbal ingredients. The heparin product includes Heparin Sodium Preparations. The Sausage Casings products include Zhu Xiaochang Sausage Casings, which are all-natural food products used for culinary purposes. The Fertilizer products is composed of Xiongguan Organic Fertilizer and Xiongguan Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Chengdu, China.

BGM Group Ltd. - Ordinary Shares - Class A

BGM Group Ltd

BGM Group (BGM) is trending due to strong community interest in its AI pivot and recent earnings report, which highlighted revenue growth driven by AI and insurance businesses. Community members are closely watching key technical levels and institutional accumulation, speculating on potential catalysts for a breakout. The stock's unique combination of AI, fintech, and robotics is generating discussion about its long-term potential and comparison to other high-growth AI companies.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors digest news of an upcoming earnings release and potential premium hikes. Community discussions revolve around the stock's recent pullback, with some anticipating a rebound driven by a possible Trump administration deal. Others are wary of regulatory scrutiny and broader sector rotation.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo ($MLGO) is trending as traders discuss its potential for a short squeeze and its connection to WIMI. The stock's small float and updates around AI and blockchain are attracting attention, with some highlighting its history of volatile runs and comparing it to other high-flying stocks. Community members are also weighing in on the company's fundamentals and potential catalysts, like a move into crypto.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as the market digests recent rate cut news and anticipates potential impacts on inflation and economic growth. Community discussions revolve around market direction, with some highlighting bullish signals and others warning of a potential downturn. Rotation into value stocks and the influence of AI on the job market are also being actively discussed.

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

89bio Inc

89bio is trending following news of its acquisition by Roche, driving excitement and speculation about the future of the MASH space. The community is discussing the potential $20.50 per share value for shareholders and what this acquisition means for other companies in the sector, with some highlighting $ETNB's long downtrend before the buyout news. Community members are now looking for the next potential buyout target in the biotech space.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares

SOXS is trending as traders discuss its continued decline despite some semi stocks showing weakness, with community members expressing frustration over the ETF's tracking and potential manipulation. Some are hoping for a market correction or hawkish comments from the Fed to provide a catalyst for a reversal. Others are speculating about potential impacts from upcoming earnings and economic data.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology ($GRRR) is trending due to a recently announced $1.4 billion contract to build AI-powered data centers in Southeast Asia. While some investors are excited about the potential revenue growth and see it as a game-changer, others are skeptical, questioning the legitimacy of the partner company, Freyr, and the details of the deal. The community is actively discussing the implications of the contract and waiting for further validation from the company.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as community members actively engage with the project's meme-driven nature, frequently asking, "What's Updog?" The Solana-based token, which has been live for over a year, is gaining attention for its community, locked liquidity pool, and being listed on the Jupiter Strict List, with holders emphasizing its potential within the dog-themed crypto space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO

Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO Alto Neuroscience, Inc. Sued for Securities Law Violations...

1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March

Alto Neuroscience represents a high-risk, high-reward opportunity.

Alto Neuroscience Inc. has struggled recently, with shares losing more than 12% over the past week, extending a decline that began in late October following disappointing Phase 2&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anro-stock-crashes-premarket-after-drug-trial-fails/cJ2L0NwReH">results</a> for its major depressive disorder (MDD) treatment, ALTO-100.&nbsp;Despite the stock sliding over 34% this year, it has not lost appeal among retail traders as Alto's follower count on Stocktwits has surged 44.6% in the past week.&nbsp;Over the last year, its retail following on the platform has grown by an astonishing 876%, suggesting that traders remain interested in the company's long-term prospects.Alto is developing treatments for central nervous system diseases and has positioned its biomarker-driven approach as a differentiator in psychiatric drug development.&nbsp;While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.&nbsp;Last month, Alto announced that a planned interim analysis of the trial had a favorable outcome, prompting the company to expand the study by approximately 50 biomarker-positive patients. Topline results from the trial are expected in mid-2026.&nbsp;The company also secured a U.S. patent for ALTO-300, covering its use as an adjunctive treatment for MDD patients who have not responded adequately to traditional antidepressants.&nbsp;The patent also includes methods for identifying eligible patients using EEG-based biomarker selection, which Alto sees as a key advantage in developing more targeted psychiatric treatments.<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ANRO_sentiment_and_message_volume_as_of_Feb_28_3028c3e1a2.png" alt="ANRO sentiment and message volume as of Feb 28.png" width="1316" height="316"><figcaption>ANRO sentiment and message volume as of Feb 28 vs a week ago | source: Stocktwits</figcaption></figure>Retail traders on Stocktwits have pointed to several potential catalysts, including reports that Jefferies sees a 500% upside for the stock.&nbsp;Some investors have also highlighted Alto's financial position, noting that the company is trading near 40% of its cash value while holding two Phase 3-ready assets and no debt.<stembedurl>https://stocktwits.com/Eternallybullish1988/message/606427653</stembedurl><stembedurl>https://stocktwits.com/BossTrade/message/606325236</stembedurl>Jones Research maintained a 'Buy' rating with an $18 price target in December, arguing that the market reaction to ALTO-100's failure was overdone.&nbsp;Last week, Alto said it would participate in a series of upcoming industry conferences in March, including the TD Cowen 45th Annual Health Care Conference, Leerink's Global Healthcare Conference, and the Stifel 2025 Virtual CNS Forum.&nbsp;With attention now focused on the ALTO-300 trial and upcoming investor events, retail investors will be hoping market sentiment around the stock tilts back into the bullish zone.Alto stock is rated ‘buy’ among six out of seven analysts covering the stock on Wall Street, with one rating ‘hold’, according to Koyfin data.Short interest, meanwhile, has edged down from 15.1% at the start of this year to 14.7% as of the end of last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 

Why Micro-Cap Alto Neuroscience's Retail Following On Stocktwits Surged Nearly 45% Last Week

Equity

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 


Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the...

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple...

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline Allink Biotherapeutics Raises $42M Series A Financing to Accelerate...

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial...

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. (Alto Neuroscience or the Company) (NYSE: ANRO...

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.69	--	--	N/A
Q2 '25	-$0.60	-$0.65	-8.58%	MISSED
Q1 '25	-$0.61	-$0.56	7.98%	BEAT
Q4 '24	-$0.65	-$0.52	19.47%	BEAT
Q3 '24	-$0.65	-$0.62	4.62%	BEAT

ANRO
Alto Neuroscience Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ANRO News

ANRO Alto Neuroscience Inc.